Defence Research and Development Organisation (DRDO) developed anti-COVID oral drug 2-deoxy-D-glucose (2-DG) has granted permission for the emergency use in severe covid-19 cases.
2-DG is different from other vaccines in usage also. It has announced that it will soon launch a 2-DG drug that will help reduce the need for oxygen. ‘2-DG’ has shown good results in clinical trials conducted on corona victims, to the extent that ‘Drugs Controller General of India (DGCI)’ approvals have been obtained for emergency use.
Following
the success of the first and second phase trials, DCGI approved the third phase
clinical trials in November last year. The drug was administered to 220
patients between December and March. The experiments were performed on patients
at 27 Covid hospitals in 10 states across the country, including Telangana and
Andhra Pradesh. By the third day of administration of the 2-DG drug,
approximately 42% of patients had no need for oxygen. So far, people use
Remdesivir for any covid related case which has great demand. Approval for 2-DG
drug becomes bitter news for black market holders.
Comments